CE: Jackie & Jill - Talking about JAK inhibitors while caring for patients with rheumatic disease (2025)

In this modular, self-learning, accredited program you will follow Jill, a pharmacist working in collaboration with rheumatologists for many years, and three rheumatology patients: Jackie, Jacqueline and Jack.

Course sections include an introduction to JAK inhibitors, the use of JAK inhibitors in clinical practice, and JAK inhibitor safety.

Course authors: Michael Boivin, pharmacist consultant and continuing education developer; Carolyn Whiskin, RPh, BScPhm, NCMP, clinical pharmacist; and Dr. Caylib Durand, PhD, MD, rheumatologist.

This course has been accredited by CCCEP for 1.5 CEUs; course #1044-2024-3914-I-P; and is available until January 3, 2026.

Learning objectives:
 

• Discuss practical considerations regarding the treatment monitoring and followup of patients treated with JAK Inhibitors
• Provide tools for pharmacists to help guide patients who are prescribed targeted-synthetic therapy, including safety and efficacy considerations
• Describe the role of pharmacists in providing care to patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA), and/or ankylosing spondylitis (AS) on JAK inhibitor therapy

This learning activity has received financial support from AbbVie Canada in the form of an educational grant.